Co-Diagnostics Inc (C97.HA)

Compare

0.2980

+0.0260

+(9.56%)

At close: 5:25:29 PM GMT+2

All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy

CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 8 days ago

CODX
Co-Diagnostics Full Year 2024 Earnings: Misses Expectations

Co-Diagnostics ( NASDAQ:CODX ) Full Year 2024 Results Key Financial Results Net loss: US$37.6m (loss widened by 6.5...

Simply Wall St. 12 days ago

CODX
Q4 2024 Co-Diagnostics Inc Earnings Call

Q4 2024 Co-Diagnostics Inc Earnings Call

Thomson Reuters StreetEvents 13 days ago

CODX
Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Despite a revenue decline, Co-Diagnostics Inc (CODX) focuses on innovation and regulatory progress to drive future growth.

GuruFocus.com 13 days ago

CODX
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024.

PR Newswire 14 days ago

CODX
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian

PR Newswire 28 days ago

CODX
The Beauty Health Company (SKIN) Reports Q4 Loss, Tops Revenue Estimates

Beauty Health (SKIN) delivered earnings and revenue surprises of 20% and 8.61%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 29 days ago

CODX
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10(b) securities class action that had been pending against the Company in the United States District Court for

PR Newswire last month

CODX
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025.

PR Newswire last month

CODX
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

On Friday, Co-Diagnostics, Inc. (NASDAQ:CODX) withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance. The company’s decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test related to shelf-life stability. Also Read: Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday? Following di

Benzinga last month

CODX
Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that, following a collaborative and informative dialogue with the Food and Drug Administration (FDA), the Company has withdrawn its 510(k) application to the FDA for its Co-Dx™ PCR COVID-19 Test on the PCR Pro™*, in favor of submitting an enhanced version of the test for 510(k) clearance.

PR Newswire last month

CODX
Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced that it will be hosting a booth at BioUtah's Life Sciences Day on the Hill today at the Utah State Capitol Rotunda.

PR Newswire 2 months ago

CODX
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025.

PR Newswire 3 months ago

CODX
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India.

PR Newswire 3 months ago

CODX
Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations

Co-Diagnostics ( NASDAQ:CODX ) Third Quarter 2024 Results Key Financial Results Net loss: US$9.70m (loss widened by 62...

Simply Wall St. 4 months ago

CODX
Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ...

Despite a significant drop in revenue, Co-Diagnostics Inc (CODX) focuses on international expansion and regulatory progress to drive future growth.

GuruFocus.com 4 months ago

CODX
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024.

PR Newswire 4 months ago

CODX
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14.

PR Newswire 5 months ago

CODX
Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 5 months ago

CODX
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts and institutional investors. Management on the call will include Dwight Egan, Chief Executive

PR Newswire 5 months ago

CODX

Performance Overview

Return	C97.HA	S&P 500 (^GSPC)
YTD	-56.18%	-10.43%
1-Year	-74.31%	+2.08%
3-Year	-94.42%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Co-Diagnostics Inc (C97.HA)

All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy

Co-Diagnostics Full Year 2024 Earnings: Misses Expectations

Q4 2024 Co-Diagnostics Inc Earnings Call

Co-Diagnostics Inc (CODX) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results

Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast

The Beauty Health Company (SKIN) Reports Q4 Loss, Tops Revenue Estimates

Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit

Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025

Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Co-Diagnostics, Inc. to Exhibit at BioUtah's 2025 Life Sciences Day on the Hill

Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Co-Diagnostics Third Quarter 2024 Earnings: Beats Expectations

Co-Diagnostics Inc (CODX) Q3 2024 Earnings Call Highlights: Navigating Revenue Decline and ...

Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024

Is Co-Diagnostics (NASDAQ:CODX) In A Good Position To Deliver On Growth Plans?

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast

Performance Overview